Adjunctive use of p16 immunohistochemistry for optimizing management of CIN lesions in a high-risk human papillomavirus-positive population.
Female
Humans
Immunohistochemistry
Cyclin-Dependent Kinase Inhibitor p16
/ analysis
Hematoxylin
Eosine Yellowish-(YS)
Uterine Cervical Neoplasms
/ pathology
Papillomavirus Infections
Biomarkers, Tumor
/ metabolism
Alphapapillomavirus
/ metabolism
Papillomaviridae
Uterine Cervical Dysplasia
/ pathology
cervical cancer
cervical intraepithelial neoplasia
human papillomavirus
immunohistochemistry
p16
Journal
Acta obstetricia et gynecologica Scandinavica
ISSN: 1600-0412
Titre abrégé: Acta Obstet Gynecol Scand
Pays: United States
ID NLM: 0370343
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
revised:
12
08
2022
received:
09
05
2022
accepted:
25
08
2022
pubmed:
1
10
2022
medline:
22
10
2022
entrez:
30
9
2022
Statut:
ppublish
Résumé
Immunostaining with p16 In this post-hoc analysis, 326 histology follow-up samples from a group of hrHPV-positive women were stained with p16 immunohistochemistry. All H&E samples were centrally revised. The pathologists reported their level of confidence in classifying the CIN lesion. Combining H&E and p16 staining resulted in a change of diagnosis in 27.3% (n = 89) of cases compared with the revised H&E samples, with a decrease of 34.5% (n = 18) in CIN1 and 22.7% (n = 15) in CIN2 classifications, and an increase of 18.3% (n = 19) in no CIN and 20.7% (n = 19) in CIN3 diagnoses. The level of confidence in CIN grading by the pathologist increased with adjunctive use of p16 immunohistochemistry to standard H&E. This study shows that adjunctive use of p16 immunohistochemistry to H&E morphology reduces the number of CIN1 and CIN2 classifications with a proportional increase in no CIN and CIN3 diagnoses, compared with standard H&E-based CIN diagnosis alone. The pathologists felt more confident in classifying the material with H&E and p16 immunohistochemistry than by using H&E alone, particularly during assessment of small biopsies. Adjunctive use of p16 immunohistochemistry to standard H&E assessment of CIN would be valuable for the diagnostic accuracy, thereby optimizing CIN management and possibly decreasing overtreatment.
Identifiants
pubmed: 36177908
doi: 10.1111/aogs.14459
pmc: PMC9812205
doi:
Substances chimiques
Cyclin-Dependent Kinase Inhibitor p16
0
Hematoxylin
YKM8PY2Z55
Eosine Yellowish-(YS)
TDQ283MPCW
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1328-1336Informations de copyright
© 2022 The Authors. Acta Obstetricia et Gynecologica Scandinavica published by John Wiley & Sons Ltd on behalf of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG).
Références
Mod Pathol. 2017 Jul;30(7):1021-1031
pubmed: 28304400
Int J Cancer. 2006 Sep 1;119(5):1095-101
pubmed: 16586444
Am J Clin Pathol. 2015 Dec;144(6):844-9
pubmed: 26572990
Am J Clin Pathol. 2016 Apr;145(4):524-30
pubmed: 27124943
Mod Pathol. 2016 Jan;29(1):51-9
pubmed: 26541274
J Low Genit Tract Dis. 2016 Jul;20(3):201-6
pubmed: 26855146
Int J Cancer. 2015 Feb 1;136(3):646-55
pubmed: 24923998
Acta Obstet Gynecol Scand. 2021 Mar;100(3):403-409
pubmed: 33037625
BMC Med. 2019 Dec 11;17(1):228
pubmed: 31829241
Acta Obstet Gynecol Scand. 2022 Nov;101(11):1328-1336
pubmed: 36177908
Mod Pathol. 2017 Feb;30(2):304-310
pubmed: 27739439
Int J Cancer. 2015 Jun 15;136(12):2741-51
pubmed: 24740700
Am J Surg Pathol. 2015 May;39(5):611-7
pubmed: 25602791
Arch Pathol Lab Med. 2012 Oct;136(10):1259-61
pubmed: 23020732
J Gynecol Oncol. 2010 Jun;21(2):87-92
pubmed: 20613897
Int J Cancer. 2021 Aug 1;149(3):707-716
pubmed: 33729551
Am J Surg Pathol. 2018 Aug;42(8):1001-1009
pubmed: 29697437
J Clin Pathol. 2018 Nov;71(11):981-988
pubmed: 30012698
BMJ. 2014 Oct 28;349:g6192
pubmed: 25352501
Am J Surg Pathol. 2008 Apr;32(4):502-12
pubmed: 18223479
Lancet Oncol. 2012 Jan;13(1):78-88
pubmed: 22177579
Cancer Med. 2020 Apr;9(7):2454-2461
pubmed: 32022461
Int J Gynecol Pathol. 2013 Jan;32(1):76-115
pubmed: 23202792
Anticancer Res. 2022 May;42(5):2599-2606
pubmed: 35489732
Pathol Res Pract. 2017 Jul;213(7):723-729
pubmed: 28554769
J Clin Pathol. 2010 Nov;63(11):972-7
pubmed: 20924035
Obstet Gynecol. 2004 Aug;104(2):250-4
pubmed: 15291995
Expert Rev Anticancer Ther. 2016 Oct;16(10):1073-85
pubmed: 27598683
Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):2130-5
pubmed: 21245294